Compugen (NASDAQ:CGEN) Given Buy Rating at HC Wainwright

Compugen (NASDAQ:CGEN - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $4.00 target price on the biotechnology company's stock. HC Wainwright's price objective would indicate a potential upside of 103.56% from the company's previous close.

Separately, Weiss Ratings upgraded shares of Compugen from a "sell (d-)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $5.00.

Compugen Price Performance

CGEN stock traded down $0.02 during midday trading on Monday, hitting $1.97. The stock had a trading volume of 158,105 shares, compared to its average volume of 366,339. The company's 50-day moving average price is $2.43 and its 200 day moving average price is $2.43. The firm has a market cap of $185.79 million, a PE ratio of 5.17 and a beta of 2.78. Compugen has a 12-month low of $1.43 and a 12-month high of $3.24.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.29 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%. During the same quarter in the previous year, the business earned ($0.08) earnings per share. As a group, sell-side analysts anticipate that Compugen will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Compugen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Platform Technology Partners raised its stake in shares of Compugen by 10.0% in the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 5,000 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Compugen by 187.5% in the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company's stock valued at $73,000 after acquiring an additional 22,500 shares during the last quarter. Bank Hapoalim BM bought a new position in Compugen during the fourth quarter worth $37,000. Calamos Advisors LLC acquired a new position in Compugen in the first quarter worth $63,000. Finally, Hillsdale Investment Management Inc. bought a new position in shares of Compugen in the 1st quarter worth about $68,000. Institutional investors and hedge funds own 12.22% of the company's stock.

Compugen Company Profile

Compugen Ltd. NASDAQ: CGEN is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system's ability to recognize and attack tumors.

Compugen's pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.